Sarah Aebersold Sells 1,091 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Sarah Aebersold sold 1,091 shares of BioLife Solutions stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total value of $27,275.00. Following the transaction, the insider now directly owns 58,816 shares in the company, valued at approximately $1,470,400. The trade was a 1.82 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Sarah Aebersold also recently made the following trade(s):

• On Monday, January 6th, Sarah Aebersold sold 240 shares of BioLife Solutions stock. The shares were sold at an average price of $27.02, for a total value of $6,484.80.

BioLife Solutions Trading Down 0.2 %

Shares of BLFS stock opened at $25.00 on Friday. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The firm has a market cap of $1.18 billion, a P/E ratio of -23.58 and a beta of 2.04. The company has a 50 day moving average of $26.62 and a 200-day moving average of $25.50. BioLife Solutions, Inc. has a 12-month low of $14.84 and a 12-month high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last released its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.32. The business had revenue of $22.71 million during the quarter, compared to the consensus estimate of $21.73 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. During the same period last year, the business posted ($0.21) earnings per share. Sell-side analysts anticipate that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on BLFS. Benchmark reiterated a “buy” rating and issued a $30.00 target price on shares of BioLife Solutions in a research note on Thursday, December 19th. HC Wainwright upped their price objective on shares of BioLife Solutions from $27.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. KeyCorp lifted their target price on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Finally, Northland Securities upped their target price on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $29.86.

Institutional Investors Weigh In On BioLife Solutions

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in BioLife Solutions by 13.2% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,686 shares of the medical equipment provider’s stock worth $1,835,000 after purchasing an additional 8,258 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in BioLife Solutions in the 4th quarter worth approximately $31,000. Point72 Asset Management L.P. bought a new position in BioLife Solutions in the 4th quarter worth approximately $11,113,000. ProShare Advisors LLC purchased a new position in BioLife Solutions in the 4th quarter valued at approximately $282,000. Finally, Millennium Management LLC raised its holdings in BioLife Solutions by 49.1% during the 4th quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider’s stock valued at $29,733,000 after acquiring an additional 377,111 shares during the period. 93.24% of the stock is currently owned by institutional investors.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.